<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02419820</url>
  </required_header>
  <id_info>
    <org_study_id>ID-TMG-102</org_study_id>
    <nct_id>NCT02419820</nct_id>
  </id_info>
  <brief_title>Dose-escalation, Repeated and Single Oral Dosing Study</brief_title>
  <official_title>Randomized, Double-blind, Placebo-controlled, Dose-escalation, Repeated and Single Oral Dosing Phase I Study to Assess the Pharmacokinetics, Pharmacodynamics and Safety of Temanogrel Co-administered With Aspirin and Clopidogrel</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IlDong Pharmaceutical Co Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>IlDong Pharmaceutical Co Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized, Double-blind, Placebo-controlled, Dose-escalation, Repeated and Single Oral
      Dosing Phase I Study to Assess the Pharmacokinetics, Pharmacodynamics and Safety of APD791
      (Temanogrel) Co-administered with Aspirin and Clopidogrel.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. To investigate pharmacokinetic and pharmacodynamic characteristics of Temanogrel when
           orally co-administered with Aspirin and/or Clopidogrel in healthy subject. a person
           determined to be suitable for the purpose of this clinical trial by investigator with
           consideration for the age and the health status of a volunteer is selected

        2. Assess the safety of Temanogrel when orally co-administered with Aspirin and/or
           Clopidogrel in healthy subjects.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">February 2016</completion_date>
  <primary_completion_date type="Anticipated">January 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics-Cmax</measure>
    <time_frame>Day1, Day2, Day3, Day4, Day 7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics-Tmax</measure>
    <time_frame>Day1, Day2, Day3, Day4, Day 7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamics-% inhibition of serotonin-stimulated platelet aggregation</measure>
    <time_frame>Day1, Day2, Day4, Day7, Day 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamics-change of serotonin-stimulated platelet aggregation</measure>
    <time_frame>Day1, Day4, Day7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamics-% inhibition of TRAP-induced platelet aggregation</measure>
    <time_frame>Day1, Day4, Day7 of every dose for mutiple dose group and first day for single dose group.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>adverse event monitoring</measure>
    <time_frame>up to post-study visit(8day±2)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>physical examination</measure>
    <time_frame>up to post-study visit(8day±2)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>vital signs</measure>
    <time_frame>up to post-study visit(8day±2)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ECG</measure>
    <time_frame>up to post-study visit(8day±2)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>laboratory test</measure>
    <time_frame>up to post-study visit(8day±2)</time_frame>
  </secondary_outcome>
  <number_of_arms>16</number_of_arms>
  <enrollment type="Anticipated">144</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>APD791 10mg single dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>APD791 10mg single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>APD791 20mg single dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>APD791 20mg single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>APD791 40mg single dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>APD791 40mg single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>APD791 10mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>APD791 10mg single dose + Aspirin + Clopidogrel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>APD791 20mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>APD791 20mg single dose + Aspirin + Clopidogrel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>APD791 40mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>APD791 40mg single dose + Aspirin + Clopidogrel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>APD791 80mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>APD791 80mg single dose + Aspirin + Clopidogrel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>APD791 160mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>APD791 160mg single dose + Aspirin + Clopidogrel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>APD791 240mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>APD791 240mg single dose + Aspirin + Clopidogrel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>APD791 320mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>APD791 320mg single dose + Aspirin + Clopidogrel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>APD791 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>APD791 placebo for single dose + Aspirin + Clopidogrel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>APD791 2mg MD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>APD791 2mg multiple dose + Aspirin + Clopidogrel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>APD791 5mg MD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>APD791 5mg multiple dose + Aspirin + Clopidogrel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>APD791 10mg MD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>APD791 10mg multiple dose + Aspirin + Clopidogrel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>APD791 20mg MD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>APD791 placebo for multiple dose + Aspirin + Clopidogrel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>APD791 placebo MD</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>APD791 placebo for multiple dose + Aspirin + Clopidogrel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>APD791</intervention_name>
    <description>Temanogrel</description>
    <arm_group_label>APD791 10mg single dose</arm_group_label>
    <arm_group_label>APD791 20mg single dose</arm_group_label>
    <arm_group_label>APD791 40mg single dose</arm_group_label>
    <arm_group_label>APD791 10mg</arm_group_label>
    <arm_group_label>APD791 20mg</arm_group_label>
    <arm_group_label>APD791 40mg</arm_group_label>
    <arm_group_label>APD791 80mg</arm_group_label>
    <arm_group_label>APD791 160mg</arm_group_label>
    <arm_group_label>APD791 240mg</arm_group_label>
    <arm_group_label>APD791 320mg</arm_group_label>
    <arm_group_label>APD791 Placebo</arm_group_label>
    <arm_group_label>APD791 2mg MD</arm_group_label>
    <arm_group_label>APD791 5mg MD</arm_group_label>
    <arm_group_label>APD791 10mg MD</arm_group_label>
    <arm_group_label>APD791 20mg MD</arm_group_label>
    <arm_group_label>APD791 placebo MD</arm_group_label>
    <other_name>Temanogrel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>Clopidogrel</description>
    <arm_group_label>APD791 10mg</arm_group_label>
    <arm_group_label>APD791 20mg</arm_group_label>
    <arm_group_label>APD791 40mg</arm_group_label>
    <arm_group_label>APD791 80mg</arm_group_label>
    <arm_group_label>APD791 160mg</arm_group_label>
    <arm_group_label>APD791 240mg</arm_group_label>
    <arm_group_label>APD791 320mg</arm_group_label>
    <arm_group_label>APD791 Placebo</arm_group_label>
    <arm_group_label>APD791 2mg MD</arm_group_label>
    <arm_group_label>APD791 5mg MD</arm_group_label>
    <arm_group_label>APD791 10mg MD</arm_group_label>
    <arm_group_label>APD791 20mg MD</arm_group_label>
    <arm_group_label>APD791 placebo MD</arm_group_label>
    <other_name>Plavix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>Aspirin</description>
    <arm_group_label>APD791 10mg</arm_group_label>
    <arm_group_label>APD791 20mg</arm_group_label>
    <arm_group_label>APD791 40mg</arm_group_label>
    <arm_group_label>APD791 80mg</arm_group_label>
    <arm_group_label>APD791 160mg</arm_group_label>
    <arm_group_label>APD791 240mg</arm_group_label>
    <arm_group_label>APD791 320mg</arm_group_label>
    <arm_group_label>APD791 Placebo</arm_group_label>
    <arm_group_label>APD791 2mg MD</arm_group_label>
    <arm_group_label>APD791 5mg MD</arm_group_label>
    <arm_group_label>APD791 10mg MD</arm_group_label>
    <arm_group_label>APD791 20mg MD</arm_group_label>
    <arm_group_label>APD791 placebo MD</arm_group_label>
    <other_name>Aspirin Protect</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for APD791</intervention_name>
    <description>Placebo for APD791</description>
    <arm_group_label>APD791 Placebo</arm_group_label>
    <arm_group_label>APD791 placebo MD</arm_group_label>
    <other_name>Placebo for Temanogrel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. a healthy adult between 20 and 45 years old at the time of visit for screening

          2. a person who is able to give written consent

          3. a person between 50 and 85 kg at the time of visit for screening

          4. a woman who is negative on a serum hCG test at the time of visit and the day before a
             trial, and who is not nursing, a woman who agrees on double contraception, medically
             approved, from the time of visit for screening to 90 days after the last
             administration of a clinical trial drug, or who had a contraceptive operation no later
             than 120 days before visit for screening, or who is menopausal, a man who had a
             contraceptive operation no later than 120 days before visit for screening, or who
             agrees on double contraception, medically approved, from the time of visit for
             screening to 90 days after the last administration of a clinical trial drug, and also
             agree not to donate sperm

          5. a person more than hemoglobin 12 g/dL at the time of screening (a woman more than
             hemoglobin 11 g/dL)

          6. a person whose vital signs were in the normal range at the time of visit for
             screening, or who is medically determined not to be clinically significant by an
             investigator

        Exclusion Criteria:

          1. a person with the medical history of gastric ulcer, duodenal ulcer or esophageal ulcer
             within 90 days from the time of visit for screening

          2. a person with the medical history of gastrointestinal diseases(e.g. Crohn's disease,
             ulcerative colitis, etc.) or surgery(excluding uncomplicated appendectomy or
             herniotomy) affecting the absorption of a clinical trial drug

          3. a person with the medical history of blood coagulation disorder or hemorrhagic
             diseases, or with clinically significant abnormal findings decided by a investigator
             on blood coagulation test at the time of screening

          4. a woman with the medical history of dysfunctional uterine bleeding within a year from
             the time of visit for screening

          5. a person with the medical history of epilepsy or convulsion

          6. a person with the medical history of internal organ transplant

          7. a person expected to be hard to complete a clinical trial because of surgery or
             medical procedures planned within a clinical trial period

          8. a person with the medical history of clinically significant new diseases within 30
             days from the time of visit for screening according to investigator's decision

          9. a person with hypersensitivity reaction to a drug or gelatin, or the medical history
             of clinically significant hypersensitivity reaction

         10. a person with the history of drug abuse, or with a positive reaction to a drug
             possible to be abused on urine drug screening

         11. a person with the medical history of alcohol abuse within two years from the time of
             visit for screening

         12. a person who is a smoker, or with a positive reaction on a urine nicotine test
             conducted at the time of visit for screening

         13. a person who donated whole blood within 60 days or constituents of blood within 30
             days, or received a blood transfusion within 30 days from the time of visit for
             screening

         14. a person taking other clinical trial drugs within 90 days from the time of visit for
             screening

         15. a person taking a prescription drug within 30 days, or a contraindicated drug or
             oriental medicine within 14 days from the time of visit for screening

         16. a person with a positive reaction to a serum test(hepatitis B test, hepatitis C test,
             HIV test, syphilis test)

         17. a person with hepatic enzymes(AST, ALT) more than 2.5 times of the reference upper
             limit(UNL) or total bilirubin more than 1.5 times of the reference upper limit(UNL) or
             creatinine more than 1.25 times of the reference upper limit(UNL)

         18. a person expected to be hard to complete a clinical trial due to physical or mental
             status according to investigator's medical decision at the time of visit for screening
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gyunseop Bae, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 27, 2015</study_first_submitted>
  <study_first_submitted_qc>April 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 17, 2015</study_first_posted>
  <last_update_submitted>April 16, 2015</last_update_submitted>
  <last_update_submitted_qc>April 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>APD791</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

